Rezolute, Inc. (RZLT) · Oct 14, 2026 · Other events

Rezolute completes tumor HI trial enrollment ahead of December data

Enrollment complete — 16-patient study fully enrolled; topline data expected mid-December 2026

Rezolute’s trial enrollment milestone keeps its tumor hyperinsulinism program on track, but December efficacy data still decide the story.

Rezolute is relying on ersodetug to build a two-indication hyperinsulinism franchise. Its congenital-HI regulatory path remains under FDA review, while the tumor-HI program is the next clean clinical catalyst; the company had already said on October 5 that upLIFT remained on track for data before year-end.

The filing removes execution risk, but not efficacy risk. The 16-patient Phase 3 upLIFT study is now fully enrolled, with topline results expected in mid-December 2026. 〔0〕 This is modestly better than simply remaining on schedule, but the timing was broadly expected, so the milestone itself does not settle the investment case.

The interim signal gives the final readout a relatively low hurdle, but the sample is tiny. Seven of the first eight participants met the responder criterion, and each discontinued intravenous glucose; however, the study needs at least 9 of 16 responders to reach the stated 56% response threshold implied by its statistical-success bar. 〔1〕 That means at least two of the remaining eight participants must respond, assuming the stated 16-participant denominator.

Safety is not currently the visible problem. Rezolute reports no drug-related safety findings so far, while the primary endpoint measures whether patients requiring intravenous glucose achieve at least a 50% reduction in glucose infusion rate. 〔2〕 The unresolved question is whether the small, single-arm dataset will produce a sufficiently robust efficacy result for a registrational and regulatory path.

Bottom line: This is a real progress milestone and keeps the tumor-HI program on schedule, but it mostly advances the story to its decisive moment. The meaningful update is still the mid-December efficacy readout, not enrollment completion itself.

What to watch next

upLIFT topline data, mid-December 2026

Original filing on SEC EDGAR

More Rezolute, Inc. news

Rezolute completes tumor HI trial enrollment ahead of December data | RZLT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.